A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

Recruiting now · Phase 1/Phase 2

Conditions studied: Cushing Syndrome, Cushing Disease, Ectopic ACTH Syndrome

In brief

A Phase 1b/2a, first-in-disease, open-label, multiple-ascending dose exploratory study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamic biomarker responses associated with CRN04894 (an adrenocorticotropic hormone \[ACTH\] receptor antagonist) in participants with ACTH-dependent Cushing's syndrome (Cushing's disease or Ectopic ACTH Syndrome \[EAS\])

Key facts

Study ID
NCT05804669
Run by
Crinetics Pharmaceuticals Inc.
People needed
18
Starts
2023-10-12
Expected to finish
2026-10-01
Last updated by the study team
2026-06-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.